Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed-release lansoprazole plus naproxen.

Monique P Curran1, Keri Wellington

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Drugs & aging·2013
Same author

Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Drugs & aging·2012
Same author

Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.

CNS drugs·2012
Same author

Live attenuated influenza vaccine (Fluenz™): a guide to its use in the prevention of seasonal influenza in children in the EU.

Paediatric drugs·2012
Same author

Crizotinib: in locally advanced or metastatic non-small cell lung cancer.

Drugs·2011
Same author

Canakinumab: in patients with cryopyrin-associated periodic syndromes.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2011
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

A new combination of lansoprazole and naproxen effectively prevents gastric ulcers in patients requiring nonsteroidal anti-inflammatory drugs (NSAIDs). This treatment significantly reduced ulcer incidence compared to placebo over 12 weeks.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) like naproxen are frequently associated with gastric ulcers.
  • Patients with a history of gastric ulcers are at higher risk when requiring NSAID therapy.

Purpose of the Study:

  • To evaluate the efficacy of a combination therapy for preventing NSAID-associated gastric ulcers.
  • To assess the safety profile of the combination therapy in high-risk patients.

Main Methods:

  • A 12-week clinical trial involving patients requiring NSAIDs with a history of gastric ulcers.
  • Participants received either delayed-release lansoprazole (15 mg once daily) plus naproxen or placebo plus naproxen.
  • Gastric ulcer incidence and treatment-related adverse events were monitored.

Related Experiment Videos

Main Results:

  • Significantly more patients on lansoprazole plus naproxen were free from gastric ulcers (80%) compared to placebo (51%) at 12 weeks (p < 0.001).
  • In a subgroup receiving naproxen, lansoprazole also showed superior ulcer prevention (89% vs 33%; p < 0.001).
  • Treatment-related adverse events were low and similar between the lansoprazole (7%) and placebo (10%) groups.

Conclusions:

  • The combination of delayed-release lansoprazole and naproxen is effective in reducing the risk of gastric ulcers in NSAID-requiring patients with a history of ulcers.
  • This combination therapy presents a favorable safety profile for managing pain while mitigating gastrointestinal risks.